In this report, we present our findings demonstrating that combining the MEK1/2 inhibitor, selumetinib, with several standard chemotherapeutic agents resulted in enhanced anti-tumour efficacy in human tumour xenograft models. This evidence concerns the gene MAP2K1 and neoplasm.